Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Relay Therapeutics (RLAY) FCF Margin (2020 - 2025)

Relay Therapeutics (RLAY) has disclosed FCF Margin for 6 consecutive years, with 641.03% as the latest value for Q4 2025.

  • On a quarterly basis, FCF Margin changed N/A to 641.03% in Q4 2025 year-over-year; TTM through Dec 2025 was 1536.08%, a 97341.0% increase, with the full-year FY2025 number at 1536.08%, up 97341.0% from a year prior.
  • FCF Margin was 641.03% for Q4 2025 at Relay Therapeutics, up from 8166.47% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 8930600.0% in Q4 2023 to a low of 58910.92% in Q2 2023.
  • A 5-year average of 546542.92% and a median of 7720.21% in 2021 define the central range for FCF Margin.
  • Peak YoY movement for FCF Margin: plummeted -49727108bps in 2021, then soared 895407628bps in 2023.
  • Relay Therapeutics' FCF Margin stood at 7609.35% in 2021, then tumbled by -209bps to 23476.28% in 2022, then soared by 38141bps to 8930600.0% in 2023, then tumbled by -100bps to 520.67% in 2024, then fell by -23bps to 641.03% in 2025.
  • Per Business Quant, the three most recent readings for RLAY's FCF Margin are 641.03% (Q4 2025), 8166.47% (Q2 2025), and 958.38% (Q1 2025).